Does TAFASITAMAB Cause Thrombocytopenia? 60 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 60 reports of Thrombocytopenia have been filed in association with TAFASITAMAB (MONJUVI). This represents 4.3% of all adverse event reports for TAFASITAMAB.
60
Reports of Thrombocytopenia with TAFASITAMAB
4.3%
of all TAFASITAMAB reports
13
Deaths
20
Hospitalizations
How Dangerous Is Thrombocytopenia From TAFASITAMAB?
Of the 60 reports, 13 (21.7%) resulted in death, 20 (33.3%) required hospitalization, and 11 (18.3%) were considered life-threatening.
Is Thrombocytopenia Listed in the Official Label?
Yes, Thrombocytopenia is listed as a known adverse reaction in the official FDA drug label for TAFASITAMAB.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
What Other Drugs Cause Thrombocytopenia?
DEXAMETHASONE (5,873)
RITUXIMAB (4,810)
CYCLOPHOSPHAMIDE (4,669)
LENALIDOMIDE (4,584)
CARBOPLATIN (4,483)
METHOTREXATE (3,865)
DOXORUBICIN (3,638)
ETOPOSIDE (3,085)
VINCRISTINE (2,940)
OXALIPLATIN (2,886)
Which TAFASITAMAB Alternatives Have Lower Thrombocytopenia Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR